Post-stroke depression (PSD) is one of the most common mental complications suffered by stroke patients leading to an impaired quality of life (QoL), altered rehabilitation outcomes, and an increased mortality rate. [1] [2] [3] [4] [5] At 3 months after a stroke, the independent predictors for PSD include a low level of education, low income, a greater severity of stroke, being younger than 68 years of age, the presence of a severe functional disability, crying behaviors, self-reported problems with activities of daily living (ADL), and the need for help during ADL. 6, 7 Additionally PSD significantly limits gait recovery after a stroke, 8,9 although the latency to the onset of rehabilitation treatment following a stroke does not limit motor recovery once the rehabilitation program is complete.
INTRODUCTION
first-onset ischemic stroke. All patients were consecutively enrolled from Department of rehabilitation at Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Korea between 2009 and 2011. A diagnosis of PSD was made by board-certified psychiatrists using criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Patients with additional Axis I psychiatric disorders other than depression were excluded to avoid any potential biases from co-morbid psychiatric disorders. The presence of co-morbid conditions was determined following an assessment of patient medication and/or clinical history by the treating physicians.
The study complied with the Declaration of Helsinki and other ethical principles regarding human experimentation. The study protocol was approved by the Institutional Review Board of Bucheon St. Mary's Hospital (IRB approval number: HC13RISI0015).
Clinical outcomes

Rating scales
All assessments were performed at baseline and at the end of the 6-month observational period. The Korean version of the Beck Depression Inventory (BDI) was used to assess the severity of depression at baseline. [12] [13] [14] To evaluate the association between baseline severity of PSD and clinical outcomes a priori defined, all subjects were classified as having either minimal-to-mild depression (MMD; BDI score of 0-16) or moderate-to-severe depression (MSD; BDI score ≥17) at baseline. 13 The modified Rankin Scale (MRS) 15 was used for the evaluation of ADL. The Berg Balance Scale (BBS) was utilized to measure balance during the performance of functional tasks. 16 The Global Deterioration Scale (GDS) 17 was used to obtain an overview of the cognitive function.
The primary clinical outcome (good outcome) was defined using a score of 1 or 2 on the MRS score at 6-month (otherwise poor outcome). 15 Additional clinical outcome used the BBS score at 6-month as following: scores of 0 to 20 for balance impairment, 21 to 40 for acceptable balance, and 41 to 56 for good balance. 16 Other endpoints were the mean changes of the GDS and BBS scores from baseline to 6-month.
Statistical analyses
For all descriptive statistics, continuous variables were presented as means with standard deviations (SD), and categorical variables were presented as frequencies. To examine group differences in socio-demographic characteristics at baseline, an analysis of variance (ANOVA) or an analysis of covariance (ANCOVA) was used for continuous variables where appropriate, and a chi-square or Fisher's exact test was used for categorical variables. The correlation coefficients for baseline BDI score, change of MRS/BBS scores, and the MRS/BBS scores at 6-month were also calculated.
The scores of the MMD and MSD groups were compared using ANOVA for symptoms and other clinical parameters that were reported as continuous variables. The mean changes in the BBS and GDS scores from baseline to 6-month were compared between the MMD and MSD groups using AN-COVA and age, number of co-morbid conditions, and baseline scores as covariates.
Logistic regression analysis was performed to determine the association between baseline severity of PSD (MSD) and the risk of a poor outcome as priori defined by MRS score. Age, sex, education level, work status, family history of stroke, past history of depression, income level, alcohol use, tobacco use, marital status, number of co-morbidities, and baseline scores of BDI, BBS, GDS, and MRS were included as covariates in the regression model. In the regression model, the dependent variable was poor outcome and the independent variable was the severity of PSD (MMD vs MSD). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and number needed to diagnose (NND) of the MSD group for poor outcome were also calculated. The odds ratio (OR) and 95% confidential intervals (CIs) were It was determined that using these statistical parameters and taking into account adjustment for covariates, the study would have a power of 80.0% to detect a medium effect of 0.4824. This corresponded to 0.4 point difference of the change in the MRS score from baseline to 6-month between the MMD and MSD groups. All statistical analyses were conducted using the NCSS 2007 ® and PASS 2008 ® software packages (NCSS LLC, Kaysville, UT, USA). Statistical significance was two-tailed and set at p<0.05.
RESULTS
Among 752 hospitalized patients 2009 to 2011, 572 patients did not meet the inclusion criteria and eventually 180 patients were enrolled. Among 180 inpatients, 110 patients were followed up for 6 months in which 91 and 56 patients had postbaseline MRS and BBS scores at 6-month ( Figure 1 ). Baseline demographics classified by MMD and MSD are presented in Table 1 . Among patients included, 127 (70.6%) were diagnosed with MMD and 53 (29.4%) were diagnosed with MSD. The mean scores of the BDI, GDS, and MRS in the MMD group were significantly lower than in the MSD group; the BBS score was higher in the MMD group than in the MSD group (Table 1) .
The OR for poor outcome in the MSD group was approximately 3.7 relative to the MMD group ( Table 2 ). The proportion of patients with better balance was significantly higher in the MMD group than in the MSD group ( Table 2 ). The mean change of the BBS score (19.8±2.7 vs. 11.4±3.0, p=0.021) from baseline to 6-month was significantly higher in the MMD group than in the MSD group, while significant difference in change of the GDS score (1.0±0.2 vs. 1.7±0.4) from baseline to 6-month was not found between the two groups. Logistic regression analyses also outlined the association between baseline severity of PSD (MSD) and poor outcome (B=1.305, S.E.=0.599, Wald=4.739, p=0.029). The sensitivity of MSD to predict poor outcome was 0.852, the specificity was 0.391, the positive predictive value was 0.371, the negative predictive value was 0.862. The NND for poor outcome in the MSD group was 4.291.
DISCUSSION
In the present study, the severity of PSD was significantly associated with clinical outcomes in stroke patients. The OR for poor outcome of the MSD group was approximately 3.7 relative to the MMD group. When the NPV was used as a predictor for poor outcome of the MSD group, patients with MMD had a probability of 86.2% for good outcome. Given the NND for poor outcome was 4.291 in the MSD group in stroke patients, thus using the severity of PSD (MSD) as a diagnostic screening test for poor outcome in stroke patients, it means that one out of 4.3 (10 of 43) of MSD stroke patient under-test should be diagnosed as poor outcome to rehabilitation treatment.
A consensus has not been established concerning the use of specific rating scales for the assessment of ADL as a primary endpoint since large variations in the choice of a primary endpoint have been proposed yet and the definitions of clinical outcome in stroke patients are still in debate. According to Sulter et al., 18 clinical outcome should be defined utilizing a mixture of different rating scales and other related clinical factors; for instance, death, institutionalization due to stroke, a MRS score >3 and a Modified Barthel Index score <60 could be used as a combined factors for such evaluation. In addition, the cutoff scores of MRS and MBI as a main rating scale should be also established in adequately-powered and well-designed clinical trials since different clinical trials have used substantially different cut-off scores of them. Only few studies investigated the relationship between PSD and balance in stroke patients to date. One previous study found that poor balance is a principal predictor of recurrent falls by stroke patients with sensitivity and specificity values ≥80%, 19 while another study determined that poor balance is significantly associated with poor QoL. 20, 21 In one such study, subjects with a fear of falling (FoF) exhibited significantly greater levels of depressive symptoms and a lower QoL than those without FoF at baseline. 22 Depressive symptoms were also an independent factor associated with falls, disabilities, previous falls, and older age in a large prospective population-based stroke incidence study with 1,104 patients. 23 Similarly, our study demonstrated the potential association between baseline severity of PSD and gait balance. The baseline BBS score of the MSD group was approximately 30% lower than that of the MMD group and the change in BBS scores from baseline to 6-month was approximately 1.7-fold higher in the MMD group than the MSD group; both of these findings favor patients with MMD over patients with MSD. An overall shift of at least 8 points is required to reveal a genuine change in function between measures at two different points in BBS score. Thus, our findings clearly demonstrate that the severity of depression exerts a potential influence on balance in stroke patients; depression may cause lack of energy/weakness and reduce the motivation on rehabilitation leading to poor restoration of gait balance.
Our study has several strengths. We utilized the MRS that is easy and validated ADL measure tool for busy clinical practice. 18 Despite balance is significantly related to falling and a poor QoL 19 in stroke patients, the measurement of depression-related gait disturbances is often ignored; we used the BBS score to evaluate the association between PSD and gait disturbance. Finally, patients with comorbid psychiatric disorders other than depression were excluded from the study.
Our study has also clear limitations. A larger sample size would have provided greater sensitivity for the detection of smaller differences between the MMD and MSD groups. Moreover, the treatment duration may be insufficient to detect long-term effects of baseline severity of PSD. 24 For example, the South London Stroke Register study, 25 which followed patients for up to 10 years, demonstrated that depression is independently associated with poor health outcomes. Other psychological factors (i.e., personality and anxiety) may influence the clinical outcomes of stroke. A neurotic personality is associated with a lower QoL in the overall domain of stroke patients 26 and anxiety has a stronger impact on QoL as a negative predictor than does depression. 27 Our study employed a naturalistic observational approach, which may overlook the details of a patient's clinical course. The number of assessment was insufficient. A significant measurement loss at 6 months follow-up (i.e., BBS) should be also considered in interpretation of our findings. It should be clearly taken into mind that a cohort study cannot determine any causal relationship between certain clinical factors (i.e., depression) and disease outcomes (i.e., stroke outcome) since study design is likely to be affected by confounders as well as hidden unknown confounders. There were also significant attrition rate due to lost-to-follow up since the majority of them moved to nursing care facilities by their families, which may also bring hidden bias for study results. Finally, we have only subdivided our samples into two populations minimal to mild and moderate to severe degree using cutoff score of 16 13 due to small sample size. When we had more sufficient sample size, we would have observed more elaborated relationship between depression and stoke outcomes among four-subpopulation of depression such as minimal, mild, moderate and severe depression. 28 This should be taken into mind in interpretation of the results. Therefore, we have found only that potential association between PSD and stroke outcomes may exist in our patients.
Our study demonstrated the potential association between PSD and clinical outcomes of first-onset stroke in Korean patients. Early detection and management of PSD in patients with first-onset stoke should be considered during routine clinical practice. This will facilitate the tailoring of specific therapies for individual patients and aid in the determination of continued management options for the treatment of these patients.
